Online inquiry

IVTScrip™ mRNA-Anti-alpha toxin&
lukE, ASN-1(Cap 1, 2-Thio-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ3290MR)

This product GTTS-WQ3290MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets alpha toxin&
lukE gene. The antibody can be applied in Staphylococcal infections research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq WP_000473596.1
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2828033; 59700577
UniProt ID P09616; A0A0H2WWN3
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-alpha toxin&
lukE, ASN-1(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) (GTTS-WQ3290MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ12535MR IVTScrip™ mRNA-Anti-PDCD1, NPVPDR001(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA NPVPDR001
GTTS-WQ12740MR IVTScrip™ mRNA-Anti-TIGIT, OMP-313M32(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA OMP-313M32
GTTS-WQ15821MR IVTScrip™ mRNA-Anti-CD3E&IL3RA, XmAb14045(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA XmAb14045
GTTS-WQ806MR IVTScrip™ mRNA-Anti-LRRC15, ABBV-085(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA ABBV-085
GTTS-WQ749MR IVTScrip™ mRNA-Anti-APP, AAB-001(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA AAB-001
GTTS-WQ9735MR IVTScrip™ mRNA-Anti-TFRC, JR-141(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA JR-141
GTTS-WQ12634MR IVTScrip™ mRNA-Anti-ERBB2, OMNITARG™(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA OMNITARG™
GTTS-WQ5012MR IVTScrip™ mRNA-Anti-GP, c4G7-N(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA c4G7-N
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW